NanoFlu/NVX CoV 2373 combination vaccine(Novavax)

N/A

Report date: 2024/12/16 16:57:04

Base Information

Drug NameNanoFlu/NVX CoV 2373 combination vaccine(Novavax)
Drug Alias NameCombined NanoFlu/NVX-CoV2373 vaccineICC vaccineNanoFlu/NVX-CoV2373 combination vaccineQuadrivalent HA nanoparticle influenza and SARS-CoV-2 rS nanoparticle combination vaccineqNIV/CoV-2373 +[8] 
ClassificationVaccines > Biological material > Viral vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsRejection of organ transplantationCoronavirus Disease 2019 (COVID-19)Multiple Myeloma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovavax
China Registration ClassN/A

Develop Information

Active CompaniesNovavaxNovavax IncMonash University
Inactive CompaniesN/A
Active IndicationsRejection of organ transplantationCoronavirus Disease 2019 (COVID-19)Multiple Myeloma +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A